Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, increasing feelings of ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...

ROME (AP) — Pope Francis remained in stable condition and didn’t need any mechanical ventilation Sunday, the Vatican said. It was a sign that he had overcome the possible complications from a ...

The advance-decline ratio (ADR) is at 0.77, close to the pandemic-era low of 0.72. It has remained below 1 for three months, signaling market weakness. Q3FY25 corporate results show sluggish revenue ...

CagriSema: Activating amylin and GLP-1 receptors CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials testing whether it can be ...

Has drug gi­ant Roche fi­nal­ly cracked DNA se­quenc­ing? The com­pa­ny has re­cent­ly claimed it can quick­ly and ac­cu­rate­ly de­code the genome, in a way that’ … ...

Now and throughout history, queer people have always been able to find each other; in spaces that aren’t queer, queer signaling is and was often found through fashion, body language, voice ...

In­vestors who were ea­ger for news of a part­ner­ing deal for the Zealand Phar­ma’s mid-stage as­set pe­tre­lin­tide had a dis­ap­point­ing Thurs­day morn­ing: The com­pa­ny re ...